Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis.

Park S, Fenaux P, Greenberg P, Mehta B, Callaghan F, Kim C, Tomita D, Xu H.

Br J Haematol. 2016 Sep;174(5):730-47. doi: 10.1111/bjh.14116. Epub 2016 May 23. Review.

2.

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S; GFM, FISM AND D-MDS.

Haematologica. 2016 Jul;101(7):e280-3. doi: 10.3324/haematol.2016.142695. Epub 2016 Apr 7. No abstract available.

3.

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

Raimbault A, Pierre-Eugene C, Rouquette A, Deudon C, Willems L, Chapuis N, Mathis S, Kunz C, Fricke H, Kosmider O, Bardet V, Fontenay M; Groupe Francophone des Myélodysplasies.

Oncotarget. 2016 Mar 22;7(12):14898-911. doi: 10.18632/oncotarget.7469.

4.

Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach.

Giordano G, Mondello P, Tambaro R, Perrotta N, D'Amico F, D'Aveta A, Berardi G, Carabellese B, Patriarca A, Corbi GM, DI Marzio L, Licianci A, Berardi D, DI Lullo L, DI Marco R.

Mol Clin Oncol. 2015 Jul;3(4):781-784. Epub 2015 Apr 29.

5.

Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

Duong VH, Baer MR, Hendrick F, Weiss SR, Sato M, Zeidan AM, Gore SD, Davidoff AJ.

Leuk Res. 2015 Jun;39(6):586-91. doi: 10.1016/j.leukres.2015.03.013. Epub 2015 Mar 28.

6.

Erythropoietin and cancer: the unintended consequences of anemia correction.

Debeljak N, Solár P, Sytkowski AJ.

Front Immunol. 2014 Nov 11;5:563. doi: 10.3389/fimmu.2014.00563. eCollection 2014. Review.

7.

Erythrocytic mobilization enhanced by the granulocyte colony-stimulating factor is associated with reduced anthrax-lethal-toxin-induced mortality in mice.

Chang HH, Chiang YW, Lin TK, Lin GL, Lin YY, Kau JH, Huang HH, Hsu HL, Wang JH, Sun DS.

PLoS One. 2014 Nov 10;9(11):e111149. doi: 10.1371/journal.pone.0111149. eCollection 2014.

8.

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.

Platzbecker U, Sekeres MA, Kantarjian H, Giagounidis A, Mufti GJ, Jia C, Yang AS, Fenaux P.

Leukemia. 2014 Dec;28(12):2418-21. doi: 10.1038/leu.2014.253. Epub 2014 Sep 2. No abstract available.

9.

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.

Tobiasson M, Dybedahl I, Holm MS, Karimi M, Brandefors L, Garelius H, Grövdal M, Högh-Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Kittang AO, Porwit A, Saft L, Möllgård L, Hellström-Lindberg E.

Blood Cancer J. 2014 Mar 7;4:e189. doi: 10.1038/bcj.2014.8.

10.

Myelodysplastic syndromes: diagnosis, prognosis, and treatment.

Germing U, Kobbe G, Haas R, Gattermann N.

Dtsch Arztebl Int. 2013 Nov 15;110(46):783-90. doi: 10.3238/arztebl.2013.0783. Review.

11.

Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.

Kornblau SM, Cohen AC, Soper D, Huang YW, Cesano A.

Cytometry B Clin Cytom. 2014 Nov;86(6):383-96. doi: 10.1002/cyto.b.21125. Epub 2013 Sep 16.

12.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M; European Leukemia Net.

Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.

13.

Current therapy of myelodysplastic syndromes.

Zeidan AM, Linhares Y, Gore SD.

Blood Rev. 2013 Sep;27(5):243-59. doi: 10.1016/j.blre.2013.07.003. Epub 2013 Jul 27. Review.

14.

Myelodysplastic syndromes: clinical practice guidelines in oncology.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M.

J Natl Compr Canc Netw. 2013 Jul;11(7):838-74.

15.

The revolution of myelodysplastic syndromes.

Sekeres MA, Bejanyan N.

Ther Adv Hematol. 2011 Feb;2(1):33-43. doi: 10.1177/2040620710395652.

16.

Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.

Davidoff AJ, Weiss SR, Baer MR, Ke X, Hendrick F, Zeidan A, Gore SD.

Leuk Res. 2013 Jun;37(6):675-80. doi: 10.1016/j.leukres.2013.02.021. Epub 2013 Mar 21.

17.

Quality of life and physicians' perception in myelodysplastic syndromes.

Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA.

Am J Blood Res. 2012;2(2):136-47. Epub 2012 May 25.

18.

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes.

Smith SW, Sato M, Gore SD, Baer MR, Ke X, McNally D, Davidoff A.

Haematologica. 2012 Jan;97(1):15-20. doi: 10.3324/haematol.2011.051755. Epub 2011 Nov 18.

19.

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Jan;9(1):30-56.

20.

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.

Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O'Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M.

BMC Med Genet. 2010 Nov 16;11:163. doi: 10.1186/1471-2350-11-163.

Supplemental Content

Support Center